383 filings
8-K
ACORQ
Acorda Therapeutics Inc
25 Apr 24
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
8:00pm
8-K
ACORQ
Acorda Therapeutics Inc
17 Apr 24
Acorda Therapeutics Announces Delisting from Nasdaq
9:10am
8-K
ACORQ
Acorda Therapeutics Inc
1 Apr 24
Acorda Therapeutics and Merz Announce Signing of “Stalking Horse” Asset Purchase Agreement
8:12pm
8-K
ACORQ
Acorda Therapeutics Inc
13 Mar 24
Amendments to Articles of Incorporation or Bylaws
4:30pm
8-K
ACORQ
Acorda Therapeutics Inc
11 Jan 24
Termination of a Material Definitive Agreement
8:33am
8-K
605jnubzg7
1 Dec 23
Other Events
4:30pm
8-K
nw6yw
13 Nov 23
Acorda Therapeutics Reports Third Quarter 2023 Financial Results
4:16pm
8-K
d121g3nfjlp7 gugsme3
8 Aug 23
Acorda Therapeutics Reports Second Quarter 2023 Financial Results
4:12pm
8-K
l79pv457gh06ced1h4y6
27 Jun 23
Departure of Directors or Certain Officers
4:35pm
8-K
oynefgnse2c0q
26 Jun 23
Other Events
4:30pm
8-K
n2f v5i53ij60l0h
2 Jun 23
Acorda Therapeutics Announces Completion of 1-for-20 Reverse Stock Split
4:28pm
8-K
4p6buhkd0i5hcjp9y
1 Jun 23
Other Events
5:17pm
8-K
tuds8u dsp
31 May 23
Other Events
5:07pm
8-K
p1o 4rnshaqcafzj02
11 May 23
Acorda Therapeutics Reports First Quarter 2023 Financial Results
4:15pm
8-K
bv788tdkscxworkz
10 May 23
Other Events
8:00am
8-K
im8t1k
8 May 23
Acorda Therapeutics and Chance Pharmaceuticals Announce Agreement to Commercialize INBRIJA® in China
5:16pm
8-K
2inls65 dybbfr
16 Mar 23
Other Events
8:16pm
8-K
79y07sn6hyb92iv
9 Mar 23
Acorda Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results
7:38am
8-K
suzbffev12eeu w7i
15 Feb 23
Acorda Therapeutics Receives Nasdaq Extension to Meet Minimum Bid Price Requirement
11:18am
8-K
mzl4l b2c3v02i58ekd
5 Jan 23
2026 manufacturing capacity expansion expected to result in further reductions in cost of goods
5:14pm